COMPASS Pathways plc (CMPS) SEC Filings & Earnings Calls

Clinical Trial Failure Risk

“Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes.” · word for word

Capital Need / Dilution Risk

“Unless and until we generate product revenue and achieve and sustain profitability, we will continue to need additional financing to fund our operations and capital expenditures.” · word for word

Regulatory / Scheduling Risk

“COMP360 psilocybin treatment is, and any future therapeutic candidates we may develop may be, subject to controlled substance laws and regulations in the jurisdictions where our products, if approved, may be marketed.” · word for word

Commercialization Risk

“We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our treatments on our own or with suitable collaborators or on an accelerated timeline.” · word for word

Regulatory and commercial execution risk

“NDA submission and FDA approval still pending; commercial launch dependent on DEA rescheduling”

Regulatory approval risk; commercial launch execution; rescheduling of psilocybin required.

“Rolling NDA submission underway; potential for accelerated review; but rescheduling and commercial readiness still required.”

Regulatory approval not guaranteed; NDA submission and review timelines may be delayed.

“Final NDA submission on track for Q4, but subject to regulatory review and potential delays.”

Net income volatility due to non-cash warrant fair value adjustments.

“Net income increase driven by $130.9M non-cash gain on fair value adjustment related to warrants.”

Dependence on single product candidate

“We are dependent on the successful development of our investigational COMP360 psilocybin treatment. We cannot give any assurance that COMP360 will successfully complete clinical trials or receive regulatory approval.” · word for word

Regulatory and scheduling risk

“Psilocybin and psilocin are listed as Schedule I controlled substances under the CSA in the U.S. For any product containing psilocybin to be available for commercial marketing in the U.S., psilocybin and psilocin must be rescheduled.” · word for word

History of losses and need for additional capital

“We have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.”

Warrant liability volatility

“During the term of our Pre-funded Warrants, which are classified as liabilities, our net loss is expected to fluctuate significantly quarter to quarter due to non-cash increases or decreases in the fair value of these Pre-funded Warrants.” · word for word

Clinical trial and development risk

“Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. Failure can occur at any time during the clinical trial process.” · word for word

Clinical and regulatory risk

“We are a late-stage, clinical biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.” · word for word

Cash burn and financing risk

“Net loss of $269.8M in 2025; company has no approved products and relies on capital markets for funding.”

Dependence on single product candidate

“Our initial focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the current treatment paradigm.” · word for word

Regulatory risk: FDA meeting outcome and NDA submission timeline could impact approval probability.

“Compass is scheduled to meet with the FDA to confirm the NDA submission strategy.” · word for word

Commercial risk: Launch readiness and market adoption of a novel psychedelic therapy in diverse healthcare settings.

“Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launch.” · word for word

Clinical-stage company with no approved products

“We are a clinical-stage biotechnology company and have not generated any revenue to date.” · word for word

Dependence on single product candidate

“We are dependent on the successful development of our investigational COMP360 psilocybin treatment.” · word for word

Regulatory and scheduling risk

“COMP360 psilocybin treatment is, and any future therapeutic candidates we may develop may be, subject to controlled substance laws and regulations in the jurisdictions where our products, if approved, may be marketed.” · word for word

Need for additional capital

“Unless and until we generate product revenue and achieve and sustain profitability, we will continue to need additional financing to fund our operations and capital expenditures.” · word for word

Debt covenant compliance risk

“Our Loan Agreement with Hercules contains financial covenants requiring us to maintain certain minimum cash balances beginning October 1, 2027 and we will need to raise additional financing or significantly reduce our operating expenses to maintain compliance with this financial covenant.” · word for word

Pre-revenue clinical-stage biotech with high cash burn and no approved product revenue

“Net loss $193.984M for 9M 2025; accumulated deficit $728.716M as of Sep 30, 2025”

Significant warrant liability and potential dilution from outstanding warrants

“Warrant liabilities $165.563M as of Sep 30, 2025; 2025 ADS Warrants exercisable at $5.7960 per ADS”

Dependence on successful clinical development and regulatory approval of COMP360 psilocybin treatment

“We are dependent on the successful development of our investigational COMP360 psilocybin treatment.” · word for word

Net loss increased significantly due to non-cash warrant liability fair value adjustments, which can cause earnings volatility.

“The increase in net loss for the quarter was primarily driven by a $101.3 million non-cash loss on fair value adjustment related to our warrant liabilities, compared with $0.0 million during the same period in 2024.” · word for word